Table 1.
List of entry inhibitors tested in clinical trials to date.
| Site of Interaction | Name of Inhibitor | Generic Name | Type of Molecule | Current Clinical Status | Reference |
|---|---|---|---|---|---|
| GP120 | Dextrane sulfate (UA001) | - | polyanion | Phase I, NCT00001009 | [230] |
| Curdlan sulfate | - | polyanion | Phase I, NCT00002100 | [231] | |
| Pro2000 | - | polyanion | Phase III, NCT00262106 | [232] | |
| Fostemsavir | Rukobia | small molecule | Approved | [233] | |
| Griffithsin gel | - | lectin | Phase I, NCT02875119 | [234] | |
| F105 | - | mAb | Phase I, NCT00001105 | [178] | |
| 3BNC117 | - | mAb | Phase I+II, NCT02588586 | [180,181] | |
| 10-1074-LS | - | mAb | Phase I, NCT03554408 | [182] | |
| VRC01 | - | mAb | Phase I+II, NCT02664415 | [184] | |
| VRC01LS | - | mAb | Phase I+II, NCT02797171 | [185] | |
| CD4-Ig2 (PRO 542) | - | bAVP | Phase I/II, NCT00055185 | [235] | |
| CCR5 | Maraviroc | Celsentri | small molecule | Approved | [236] |
| INCB009471 | - | small molecule | Phase II, NCT00393120 | [237] | |
| PF-232798 | - | small molecule | Phase II, NCT00495677 | [238] | |
| TAK-652 | Cenicriviroc | small molecule | Phase II, NCT01092104 | [239] | |
| MK-4176, SCH 417690 | Viciviroc | small molecule | Phase III, NCT00474370 | [240] | |
| GW873140, AK602 | Aplaviroc | small molecule | Phase II+III terminated, NCT00197145 | [241] | |
| HGS004 | - | mAb | Phase I, NCT00114699 | [242] | |
| PRO 140 | Leronlimab | mAb | Phase II/III, NCT03902522 | [243] | |
| CXCR4 | AMD11070 | - | small molecule | Phase I/II, NCT00089466 | [244] |
| GP41 | Enfuvirtide | Fuzeon | peptide | Approved | [245] |
| Albuvirtide | - | protein-conjugate | Phase II+III, NCT04560569 | [246] | |
| C34-CXCR4 | - | cell | Phase I, NCT03020524 | [247] | |
| 2F5/4E10 | - | mAb | Phase I/II, NCT00219986 | [248] | |
| 10E8.4/iMab | - | bAVP | Phase I, NCT03875209 | [249] | |
| CD4 | Ibalizumab (TNX-355) | Trogarzo | mAb | Approved | [250] |